Methylthioninium Chloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Methylthioninium Chloride |
| DrugBank ID | DB08167 |
| Brand Names (EU) | Lumeblue (previously Methylthioninium chloride Cosmo) |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 90.43% |
Approved Indication (EMA)
Lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | irritable bowel syndrome | 90.43% | DL |
| 2 | dysthymic disorder | 88.53% | DL |
| 3 | anaphylaxis | 88.06% | DL |
| 4 | food-dependent exercise-induced anaphylaxis | 87.75% | DL |
| 5 | bronchitis | 85.52% | DL |
| 6 | anxiety | 80.59% | DL |
| 7 | obsolete rare pulmonary disease | 75.18% | DL |
| 8 | variably protease-sensitive prionopathy | 74.85% | DL |
| 9 | autonomic nervous system disease | 74.49% | DL |
| 10 | pulmonary edema | 73.87% | DL |
| 11 | pityriasis simplex | 73.45% | DL |
| 12 | multiple system atrophy | 72.85% | DL |
| 13 | cauda equina syndrome | 70.95% | DL |
| 14 | primary hereditary glaucoma | 69.87% | DL |
| 15 | acrodermatitis chronica atrophicans | 67.77% | DL |
| 16 | dermatitis | 67.09% | DL |
| 17 | obsolete neurogenic bladder (disease) | 66.70% | DL |
| 18 | neurocirculatory asthenia | 65.82% | DL |
| 19 | open-angle glaucoma | 65.72% | DL |
| 20 | benign paroxysmal torticollis of infancy | 65.45% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.